| Richard W Glover Dds Ms | |
|
2310 Nott St East Niskayuna NY 12309 | |
| (518) 374-3060 | |
| (518) 374-5278 |
| Full Name | Richard W Glover Dds Ms |
|---|---|
| Speciality | Dentist - General Practice |
| Location | 2310 Nott St East, Niskayuna, New York |
| Authorized Official Name and Position | Nicholas J Chauvin (OWNER) |
| Authorized Official Contact | 5183743060 |
| Accepts Medicare Insurance | This clinic does not participate in Medicare Program. |
| Mailing Address | Practice Location Address |
|---|---|
| Richard W Glover Dds Ms 2310 Nott St East Niskayuna NY 12309 Ph: (518) 374-3060 | Richard W Glover Dds Ms 2310 Nott St East Niskayuna NY 12309 Ph: (518) 374-3060 |
| NPI Number | 1295802122 |
|---|---|
| Provider Enumeration Date | 11/29/2006 |
| Last Update Date | 11/30/2015 |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1295802122 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 1223G0001X | Dentist - General Practice | 038561 (New York) | Primary |
News Archive
A team led by Dana-Farber Cancer Institute scientists has developed a more human-like mouse model of cancer they say will aid the search for cancer-causing genes and improve the predictive value of laboratory drug testing.
Edison Pharmaceuticals, Inc. announced today preliminary results obtained on a 28-day phase 2A clinical trial in Friedreich's ataxia. While the primary endpoint of glucose disposition index did not show statistically significant improvement, EPI-A0001 did significantly improve neurological function as assessed by the Friedreich's Ataxia Rating Scale.
A pregnancy is not always a happy event and as many as 10-15 per cent of pregnant women in Denmark have depressive symptoms. Despite years of critical focus on the side effects of antidepressants in the healthcare system, consumption of antidepressants by pregnant women actually increased drastically during the period 1997 to 2011.
Researchers have investigated publicly available data published to investigate the proportion of the US population that has become immune to SARS-CoV-2.
CoDa Therapeutics, Inc., a biopharmaceutical company focused on the development and commercialization of therapeutics for wound care and tissue repair, today announced positive results from its Phase 2 NOVEL Study of NEXAGON® in patients with chronic venous leg ulcers. NEXAGON® is a topically applied, novel therapeutic candidate, with the potential to revolutionize the wound healing treatment paradigm by leveraging a new mechanism and target involved in the healing process.
› Verified 6 days ago
Capital District Endodontics, Pc Dental Clinic Medicare: Not Enrolled in Medicare Practice Location: 2317 Balltown Rd, Suite 201, Niskayuna, NY 12309 Phone: 518-377-1234 |